Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART-V)

Inclusion Criteria: * Aged 18 or over * Histologically proven single primary site colorectal adenocarcinoma * Stage II/III colorectal cancer planned for surgical resection and no clinical indication for neoadjuvant preoperative chemotherapy/chemoradiation therapy * WHO performance status 0,1 or 2 * Adequate full blood count: White Cell Count (WCC) \>3.0 x 109 /l; Platelets \>100 x 109/l; Haemoglobin (Hb) \>8g/dL * Adequate renal function : Glomerular Filtration Rate \>30ml/min by Cockcroft-Gault formula * Adequate hepatobiliary function : Bilirubin \< 3 x Upper limit normal * Female participants of child bearing potential must have a negative pregnancy test \< 72 hours prior to initiating study intervention and agree to avoid pregnancy using contraceptive precautions for up to 6 weeks after the last dose of study treatment intervention * Male participants with a partner of childbearing potential must agree to use contraceptive precautions during and for up to 6 weeks after the last dose of the study treatment intervention * Patient able and willing to provide written, informed consent for the study Exclusion Criteria: * Contraindication to the use of artesunate due to hypersensitivity * Pregnancy or lactation * History of immunosuppression * History of hearing or balance problems * Weight \< 42 kg or \> 110 kg * Other planned intervention, apart from Vietnamese standard of care * Any other malignant disease diagnosis within the preceding 2 years with the exception of non-melanomatous skin cancer and carcinoma in situ * Lactose intolerance